Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-α
Oxygen deprivation (hypoxia) is a common feature of solid tumors in advanced stages. The primary cellular transcriptional responses to hypoxia are mainly mediated by the transcription factor hypoxia-inducible factor (HIF). HIF consists of an oxygen-labile α -subunit (HIF-1 α , -2 α ) and a stable β...
Saved in:
Published in | Cell death & disease Vol. 5; no. 7; p. e1322 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
10.07.2014
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Oxygen deprivation (hypoxia) is a common feature of solid tumors in advanced stages. The primary cellular transcriptional responses to hypoxia are mainly mediated by the transcription factor hypoxia-inducible factor (HIF). HIF consists of an oxygen-labile
α
-subunit (HIF-1
α
, -2
α
) and a stable
β
-subunit (ARNT). Prolyl-4-hydroxylase 2 (PHD2) is known as an important mediator of the oxygen-dependent degradation of HIF-
α
subunits. As HIF-
α
subunits are not confirmed to be the only substrates of PHD2, it is unknown whether PHD2 regulates HIF-1
α
and HIF-2
α
by interacting with other intracellular molecules. In this study, we found that in the glioblastoma cells, PHD2 maintains the gene expression of HIF-1
α
in dependence of nuclear factor
κ
B and suppresses the gene expression of HIF-2
α
through HIF-1
α
. The PHD2-mediated degradation of HIF-1
α
and HIF-2
α
seems less important. Furthermore, PHD2 enhances hypoxia-induced glioblastoma cell death by modulating the expression of the HIF target genes glucose transporter 1, vascular endothelial growth factor-A and Bcl-2 binding protein 3. Our findings show that PHD2 inhibits the adaptation of glioblastoma cells to hypoxia by regulating the HIF-
α
subunits in a non-canonical way. Modulation of PHD2 activity might be considered as a new way to inhibit glioblastoma progression. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2041-4889 2041-4889 |
DOI: | 10.1038/cddis.2014.295 |